Company InfoNewsInvestor InformationResearchDevelopmentCareersBusiness DevelopmentResourcesDrugs databaseBack to the home pageSearch  
Drugs database
Drugs A-Z

Brands A-Z

Drugs by categories

Drugs by manufacturer

Drugs by packager

Antibiotics for sale

Online Viagra bestellen in Nederland

Home / Drugs / Starting with C / Clindamycin

Clindamycin is a semisynthetic lincosamide antibiotic that has largely replaced lincomycin due to an improved side effect profile. Clindamycin inhibits bacterial protein synthesis by binding to bacterial 50S ribosomal subunits. It may be bacteriostatic or bactericidal depending on the organism and drug concentration.
Cleocin Hcl
Cleocin Pediatric
Cleocin Phosphate
Cleocin T
Cleocin T Gel
Cleocin T Lotion
Cleocin T Topical Solution
Dalacin C
Dalacin C Flavored Granules
Dalacin C Phosphate
Dalacin T Topical Solution
ResiDerm A
CategoriesAnti-Bacterial Agents
Protein Synthesis Inhibitors
ManufacturersPharmacia and upjohn co
Aurobindo pharma ltd
Corepharma llc
Lannett holdings inc
Ranbaxy laboratories ltd
Teva pharmaceuticals usa inc
Watson laboratories inc
Zydus pharmaceuticals usa inc
Paddock laboratories inc
Perrigo uk finco ltd partnership
Stiefel laboratories inc
Nycomed us inc
Kv pharmaceutical co
Galderma laboratories lp
Altana inc
Abraxis pharmaceutical products
App pharmaceuticals llc
Astrazeneca lp
Baxter healthcare corp anesthesia and critical care
Bedford laboratories div ben venue laboratories inc
Bristol myers squibb pharma co
Hospira inc
Loch pharmaceuticals inc
Marsam pharmaceuticals llc
Solopak laboratories inc
Teva parenteral medicines inc
Abbott laboratories
Baxter healthcare corp
Actavis mid atlantic llc
Boca pharmacal inc
Copley pharmaceutical inc
E fougera div altana inc
Perrigo new york inc
Stiefel a gsk co
Taro pharmaceutical industries ltd
Versapharm inc
Wockhardt eu operations (swiss) ag
Perrigo co
PackagersAccra Pac Inc.
Aidarex Pharmacuticals LLC
Ameri-Pac Inc.
Amerisource Health Services Corp.
Apotheca Inc.
APP Pharmaceuticals
A-S Medication Solutions LLC
Aurobindo Pharma Ltd.
Baxter International Inc.
Bedford Labs
Ben Venue Laboratories Inc.
Bryant Ranch Prepack
Cardinal Health
Catalent Pharma Solutions
Contract Pharm
Corepharma LLC
Coria Laboratories
Coupler Enterprises Inc.
Dermik Labs
Direct Dispensing Inc.
Dispensing Solutions
Diversified Healthcare Services Inc.
Dow Pharmaceutical Sciences
DPT Laboratories Ltd.
E. Fougera and Co.
Galderma Laboratories
Greenstone LLC
H.J. Harkins Co. Inc.
Heartland Repack Services LLC
Hospira Inc.
Innoviant Pharmacy Inc.
Inyx Usa Ltd.
Kaiser Foundation Hospital
Keltman Pharmaceuticals Inc.
Kleen Test Products Corp.
KV Pharmaceutical Co.
Lake Erie Medical and Surgical Supply
Lannett Co. Inc.
Liberty Pharmaceuticals
Major Pharmaceuticals
Mckesson Corp.
Medisca Inc.
Murfreesboro Pharmaceutical Nursing Supply
Novopharm Ltd.
Nucare Pharmaceuticals Inc.
Nycomed Inc.
Ohm Laboratories Inc.
Paddock Labs
Palmetto Pharmaceuticals Inc.
Patheon Inc.
PD-Rx Pharmaceuticals Inc.
Perrigo Co.
Pfizer Inc.
Pharmaceutical Utilization Management Program VA Inc.
Pharmacia Inc.
Physician Partners Ltd.
Physicians Total Care Inc.
Preferred Pharmaceuticals Inc.
Prepackage Specialists
Prepak Systems Inc.
Quality Care
Ranbaxy Laboratories
Rebel Distributors Corp.
Redpharm Drug
Remedy Repack
Resource Optimization and Innovation LLC
Sanofi-Aventis Inc.
Sirius Labs
Southwood Pharmaceuticals
Spectrum Pharmaceuticals
St Mary's Medical Park Pharmacy
Stat Rx Usa
Stiefel Labs
Taro Pharmaceuticals USA
Teva Pharmaceutical Industries Ltd.
Ther-Rx Corp.
Tya Pharmaceuticals
UDL Laboratories
Unimed Pharmaceuticals Inc.
Watson Pharmaceuticals
Wockhardt Ltd.
SynonymsClindamicina [INN-Spanish]
Clindamycin Hydrochloride
Clindamycin Phosphate
Clindamycine [French]
Clindamycine [INN-French]
Clindamycinum [INN-Latin]


For the treatment of serious infections caused by susceptible anaerobic bacteria, including Bacteroides spp., Peptostreptococcus, anaerobic streptococci, Clostridium spp., and microaerophilic streptococci. May be useful in polymicrobic infections such as intra-abdominal or pelvic infections, osteomyelitis, diabetic foot ulcers, aspiration pneumonia and dental infections. May also be used to treat MSSA and respiratory infections caused by S. pneumoniae and S. pyogenes in patients who are intolerant to other indicated antibiotics or who are infected with resistant organism. May be used vaginally to treat vaginosis caused by Gardnerella vaginosa. Clindamycin reduces the toxin producing effects of S. aureus and S. pyogenes and as such, may be particularly useful for treating necrotizing fasciitis. May be used topically to treat acne.


Clindamycin is an antibiotic, similar to and a derivative of lincomycin. Clindamycin can be used in topical or systemic treatment. It is effective as an anti-anaerobic antibiotic and antiprotozoal.

mechanism of action

Systemic/vaginal clindamycin inhibits protein synthesis of bacteria by binding to the 50S ribosomal subunits of the bacteria. Specifically, it binds primarily to the 23s RNA subunit. Topical clindamycin reduces free fatty acid concentrations on the skin and suppresses the growth of Propionibacterium acnes (Corynebacterium acnes) , an anaerobe found in sebaceous glands and follicles.


Adverse effects include nausea (may be dose-limiting), diarrhea, pseudomembranous colitis, allergic reactions, hepatoxicity, transient neutropenia and eosinophilia and agranulocytosis. Pseudomembranous colitis occurs in 0.01 - 10% of patients and occurs more commonly than with other antibiotics. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin.




Rapidly absorbed after oral administration with peak serum concentrations observed after about 45 minutes. Absorption of an oral dose is virtually complete (90%) and the concomitant intake of food does not appreciably modify the serum concentrations; serum levels have been uniform and predictable from person to person and dose to dose. Clindamycin does not penetrate the blood brain barrier.

half life

2.4 hours

route of elimination

Approximately 10% of the bioactivity is excreted in the urine and 3.6% in the feces; the remainder is excreted as bioinactive metabolites.

drug interactions

Aluminium: The aluminium salt decreases the absorption of lincosamides

Atracurium: The agent increases the effect of muscle relaxant

Attapulgite: The aluminium salt decreases the absorption of lincosamides

Cyclosporine: Clindamycin may decrease the therapeutic effect of cyclosporine.

Dihydroxyaluminium: The aluminium salt decreases the absorption of lincosamides

Doxacurium chloride: The agent increases the effect of muscle relaxant

Kaolin: The aluminium salt decreases the absorption of lincosamides

Metocurine: The agent increases the effect of muscle relaxant

Mivacurium: The agent increases the effect of muscle relaxant

Pancuronium: The agent increases the effect of muscle relaxant

Pipecuronium: The agent increases the effect of muscle relaxant

Rocuronium: The agent increases the effect of muscle relaxant

Succinylcholine: The agent increases the effect of muscle relaxant

Tubocurarine: The agent increases the effect of muscle relaxant

Vecuronium: The agent increases the effect of muscle relaxant